Andreas Neisius

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 627 citations · Full text

First-line Therapy, Urology, Chemotherapy Versus Chemotherapy +7

EAU Guidelines on Assessment and Nonsurgical Management of Urinary Incontinence

Malcolm G Lucas, Ruud Bosch, Fiona C. Burkhard et al. · European Urology · 2012 · 418 citations

Urology, Voiding Dysfunction, Patient Safety +7

EAU Guidelines on Urinary Incontinence

Joachim W. Thüroff, Paul Abrams, Karl‐Erik Andersson et al. · European Urology · 2010 · 380 citations

Urology, Voiding Dysfunction, Pelvic Prolapse +5

EAU Guidelines on Surgical Treatment of Urinary Incontinence

Malcolm G Lucas, Ruud Bosch, Fiona C. Burkhard et al. · European Urology · 2012 · 290 citations

Urology, Voiding Dysfunction, Eau Guidelines +3

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 262 citations · Full text